Open AccessPidotimod: In-depth review of current evidence
Author(s) -
Ashok Mahashur,
P. K. Thomas,
Parthiv Mehta,
Kundan Nivangune,
Snehal Muchhala,
Rishi Jain
Publication year - 2019
Publication title -
lung india
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_39_19
Subject(s) - medicine , immunostimulant , chronic bronchitis , bronchiectasis , bronchitis , copd , intensive care medicine , pneumonia , immunology , immune system , lung
Pidotimod, an immunostimulant, is researched for over two decades. Current evidence indicates its utility in a variety of indications in children as well as in adults. Its immunostimulant activity has been firmly established in the management of recurrent respiratory infections in children with or without asthma. Compared to standard of care alone, addition of pidotimod to standard of care significantly prevents the recurrences and reduces the severity and duration of acute episodes, ultimately resulting in reduced visits to pediatric clinics and lower absenteeism at school. In adults, pidotimod is effective in the prevention and treatment of acute infectious exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). Further, it has been evaluated in indications such as pneumonia, hand-food-mouth disease, bronchiectasis, and chronic idiopathic urticaria. From a total of 32 studies conducted in child (24 studies) and adult (8 studies) population, this in-depth review discusses the current evidence of pidotimod. With further exploration, the immunostimulant activity of pidotimod might be extended to different immunological disorders.